THI OBI

Serial Number 98424308
690

Registration Progress

Application Filed
Feb 27, 2024
Under Examination
Oct 1, 2024
Approved for Publication
Aug 6, 2024
Published for Opposition
Aug 6, 2024
Registered

Trademark Image

THI OBI

Basic Information

Serial Number
98424308
Filing Date
February 27, 2024
Published for Opposition
August 6, 2024
Drawing Code
3

Status Summary

Current Status
Active
Status Code
690
Status Date
Oct 27, 2025
Application
Pending
Classes
001 005 042 044

Rights Holder

OBI PHARMA, INC.

03
Address
Nangang Dist.
6F., No. 508, Sec. 7, Zhongxiao E. Rd.
Taipei City 115011
TW

Ownership History

OBI PHARMA, INC.

Original Applicant
03
Taipei City TW

OBI PHARMA, INC.

Owner at Publication
03
Taipei City TW

Legal Representation

Attorney
Ran He

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

22 events
Date Code Type Description Documents
Oct 27, 2025 OTHE I CASE RETURNED TO EXAMINATION Loading...
Oct 27, 2025 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Oct 27, 2025 PCBG O PETITION TO DIRECTOR - CHANGE BASIS - GRANTED Loading...
Oct 22, 2025 APET A ASSIGNED TO PETITION STAFF Loading...
Sep 22, 2025 TPAD I TEAS PETITION TO AMEND BASIS RECEIVED Loading...
Mar 3, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 17, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 16, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 16, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 1, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 6, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 6, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 17, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 27, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 27, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jun 27, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jun 27, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jun 27, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jun 26, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 4, 2024 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Apr 3, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 1, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 001
Carbide; Cellulose; Glycogen; Glycoprotein; Sulfides; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Adjuvants, other than for medical or veterinary purposes; Antioxidants for use in the manufacture of pharmaceuticals; Biochemical catalysts; Biological preparations for use in industry and science; Carbonic hydrates; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Fatty acids for use in pharmaceutical; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Protein in raw material form for scientific and medical research; Proteins for use in manufacture; Proteins for use in the manufacture of drugs
Class 005
Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents
Class 042
Biological research; Biological research and analysis; Chemical analysis; Chemical research; Chemical research and analysis; Chemical research services; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research; Medical research in the field of oncology; Medical research services; Medical research services in the field of cancer; Pharmaceutical research and development; Providing information about medical research in the field of cancer, oncology; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research in the field of genetics; Technical research in the field of pharmaceutical studies
Class 044
Administering vaccines to patients; Alternative medicine services; Cancer screening services; Cultured cell bank services for medical transplantation; Health care; Health care services for treating cancer; Health assessment services; Health counselling; Human tissue bank services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical assistance; Medical screening; Medical treatment using cultured cells; Nursing, medical; Occupational therapy; Providing health information in the field of cancer prevention and treatment; Providing information in the field of cancer prevention, screening, diagnosis and treatment; Regenerative medicine services; Remote monitoring of medical data for medical diagnosis and treatment; Telemedicine services

Additional Information

Design Mark
The mark consists of The "Thi" is black, the "OBI" is teal. Below OBI is a teal underline.
Color Claim
The color(s) black and teal is/are claimed as a feature of the mark.

Classification

International Classes
001 005 042 044